Materiały źródłowe

• #1 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  Most people with NAFLD will not develop any serious problems, but if you’re diagnosed with the condition it’s a good idea to take steps to stop it getting any worse. […] There’s currently no specific medication for NAFLD, but making healthy lifestyle choices can help. […] Treatment also may be recommended for associated conditions (high blood pressure, diabetes and cholesterol) or complications. […] You may be advised to have regular appointments with your doctor to check your liver function and look for signs of any new problems. […] There’s not currently any medicine that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medicine to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and treat obesity.

• #2 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  Early diagnosis of NAFLD, along with following medical advice, can reduce a persons chance NAFLD progressing to NASH and cirrhosis. […] There are no medications approved yet for nonalcoholic fatty liver disease (now called MASLD). Eating a healthy diet and adding physical movement to your day may help prevent liver damage from starting or reverse it in the initial stages. Here are suggestions for people who have NAFLD: See a liver specialist (gastroenterologist or hepatologist) to monitor and advise you about your liver health. If you are overweight or obese, speak to your doctor or a dietitian to learn more about planning healthy meals that can help you lose weight. If you have high cholesterol or high triglycerides, speak with your doctor about how to lower your numbers to a healthier range. If you have diabetes, speak with your doctor about managing your condition. Avoid alcohol (beer, wine, hard liquor) to lower the risk of additional liver damage.

• #3 Treatment for NAFLD & NASH – NIDDK

  https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/treatment

  Doctors recommend weight loss to treat nonalcoholic fatty liver disease, or NAFLD (also referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD). Weight loss can reduce fat in the liver. Weight loss can also reduce inflammation and fibrosis or scarring in the liver due to nonalcoholic steatohepatitis, or NASH (also referred to as metabolic dysfunction-associated steatohepatitis, or MASH). […] Losing at least 3% to 5% of your body weight can reduce fat in the liver. You may need to lose up to 7% to 10% of your body weight to reduce liver inflammation and fibrosis. […] Doctors recommend gradually losing weight to improve NAFLD. Rapid weight loss and malnutrition can make liver disease worse. […] No medicines have been approved to treat NAFLD either NAFL or NASH. However, researchers are studying medicines that may improve these conditions. […] If NASH leads to cirrhosis, doctors can treat many complications of cirrhosis with medicines, minor medical procedures, and surgery. People with liver failure or liver cancer may need a liver transplant to restore health.

• #4 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. The following lifestyle changes are important in managing your disease. […] This is one of the best treatments for NAFLD and NASH, because it moderates the conditions that contribute to fatty liver disease. Losing just 3 to 5 percent of your body weight can reduce fat in your liver; losing 7 percent can decrease inflammation as well. If you are overweight or obese, doctors typically recommend you gradually lose 7 to 10 percent of your body weight over the course of one year. Rapid weight loss through fasting is not recommended, as it can make NAFLD worse. […] While following a healthy diet and maintaining a normal body weight may not seem like a specific treatment, its essential to managing NAFLD and NASH.

• #5 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. The following lifestyle changes are important in managing your disease. […] This is one of the best treatments for NAFLD and NASH, because it moderates the conditions that contribute to fatty liver disease. Losing just 3 to 5 percent of your body weight can reduce fat in your liver; losing 7 percent can decrease inflammation as well. If you are overweight or obese, doctors typically recommend you gradually lose 7 to 10 percent of your body weight over the course of one year. Rapid weight loss through fasting is not recommended, as it can make NAFLD worse. […] While following a healthy diet and maintaining a normal body weight may not seem like a specific treatment, its essential to managing NAFLD and NASH.

• #6 MASLD, NAFLD and fatty liver disease – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/masld-nafld-and-fatty-liver-disease/

  Metabolic dysfunction-associated steatotic liver disease (MASLD) is a long-lasting liver condition caused by having too much fat in the liver. […] The main treatment is eating a well-balanced diet, being physically active and (if needed) losing weight. Research shows these can reduce liver fat and in some cases reverse MASLD. […] Treating MASLD with a healthy diet, physical activity and weight loss can slow or even reverse liver damage, especially if it is at an earlier stage. […] The main treatment is eating a healthy diet, being more physically active and (if needed) losing weight. This might seem like very general advice, but these steps all reduce liver fat and inflammation. For example, for people who are overweight, evidence shows losing 5 to 10% of their bodyweight can stop and sometimes even reverse liver damage.

• #7 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development. […] There are no current FDA-approved medications for NAFLD. Lifestyle modifications of 5%-10% weight loss through hypocaloric diets, aerobic exercise, and resistance training have been strongly advocated for by the AGA, AASLD, and EASL guidelines. A weight loss of 5% of TBW can decrease hepatic steatosis, and 10% weight loss has been shown to stabilize or even reverse fibrosis from NAFLD. This weight loss has been advocated through methods such as a hypocaloric diet, intermittent fasting, and aerobic exercise.

• #8 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Treatments for nonalcoholic fatty liver disease include weight loss, exercise, improved diabetes control and the use of cholesterol-lowering medications. […] The best treatment for you depends on the underlying cause of your nonalcoholic fatty liver disease. Preferred treatments include: Weight loss and exercise. If your body mass index is above 25, a diet and exercise program may reduce the amount of accumulated fat in your liver. The most effective diet is rich in fiber and low in calories and saturated fat, with total fat accounting for no more than 30 percent of total calories. But go slowly. Aim to lose 10 percent of your body weight over six months, because rapid weight loss may lead to a worsening of liver disease. Even if you aren’t overweight or obese, a healthy diet and daily physical activity may reduce inflammation, lower elevated levels of liver enzymes and decrease insulin resistance.

• #9 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Treatments for nonalcoholic fatty liver disease include weight loss, exercise, improved diabetes control and the use of cholesterol-lowering medications. […] The best treatment for you depends on the underlying cause of your nonalcoholic fatty liver disease. Preferred treatments include: Weight loss and exercise. If your body mass index is above 25, a diet and exercise program may reduce the amount of accumulated fat in your liver. The most effective diet is rich in fiber and low in calories and saturated fat, with total fat accounting for no more than 30 percent of total calories. But go slowly. Aim to lose 10 percent of your body weight over six months, because rapid weight loss may lead to a worsening of liver disease. Even if you aren’t overweight or obese, a healthy diet and daily physical activity may reduce inflammation, lower elevated levels of liver enzymes and decrease insulin resistance.

• #10 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant. […] Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #11 Non-alcoholic fatty liver disease (NAFLD) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/non-alcoholic-fatty-liver-disease-nafld/

  Most people with NAFLD wont develop any serious problems, but if youre diagnosed with the condition its a good idea to take steps to stop it getting any worse. […] Theres currently no specific medication for NAFLD, but making healthy lifestyle choices can help and treatment may be recommended for associated conditions (high blood pressure, diabetes and cholesterol) or complications. […] Adopting a healthy lifestyle is the main way of managing NAFLD. The following can all help. […] Lose weight you should aim for a BMI of 18.5-24.9. Losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it. […] Eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt. Eating smaller portions of food can help too.

• #12 Treatment Options and Continuity of Care in MAFLD

  https://www.ecrjournal.com/articles/treatment-options-and-continuity-care-metabolic-associated-fatty-liver-disease?language_content_entity=en

  Current clinical practice guidelines agree that the cornerstone of MASLD treatment in obese/overweight patients is a lifestyle intervention involving changes in diet and physical activity, aiming for a weight reduction of 7-10% and a calorie reduction of 500-1,000 kcal/day. […] Evidence suggests that calorie restriction can improve numerous metabolic parameters beyond its effect on liver-related outcomes. […] The Mediterranean diet is the only diet recommended as a potential therapy for MASLD by several scientific societies: the European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of Obesity. […] Although weight loss is the main goal, several systematic reviews have shown that exercise even at low level, without associated weight loss, can reduce intrahepatic lipid (IHL).

• #13 Treatment Options and Continuity of Care in MAFLD

  https://www.ecrjournal.com/articles/treatment-options-and-continuity-care-metabolic-associated-fatty-liver-disease?language_content_entity=en

  Current clinical practice guidelines agree that the cornerstone of MASLD treatment in obese/overweight patients is a lifestyle intervention involving changes in diet and physical activity, aiming for a weight reduction of 7-10% and a calorie reduction of 500-1,000 kcal/day. […] Evidence suggests that calorie restriction can improve numerous metabolic parameters beyond its effect on liver-related outcomes. […] The Mediterranean diet is the only diet recommended as a potential therapy for MASLD by several scientific societies: the European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of Obesity. […] Although weight loss is the main goal, several systematic reviews have shown that exercise even at low level, without associated weight loss, can reduce intrahepatic lipid (IHL).

• #14 Fatty Liver Disease: What To Know | Northwestern Medicine

  https://www.nm.org/healthbeat/healthy-tips/Fatty-Liver-Disease-What-to-Know

  Nutritional changes and physical activity have shown to be an effective treatment for MASLD. Weight loss can help fight fat buildup, inflammation and fibrosis in your liver. […] „General dietary recommendations include avoidance of high fructose corn syrup (such as soda and sweetened beverages) and limiting carbohydrates in the diet,” says Dr. Boike. „The Mediterranean diet has also been shown to be beneficial, especially if patients have underlying metabolic syndrome.” […] In March 2024, the U.S. Food and Drug Administration (FDA) approved resmetirom, which is the first available medication to treat MASH with fibrosis but not yet cirrhosis. Talk to your care team about if medication is right for you. […] To help prevent fat buildup in your liver, stay physically active, eat a healthy diet, maintain a healthy weight and limit alcohol to safe limits (no more than one drink a day for women* or two for men). Connect with your care team if you have a hard time with any of these they can help you make a plan that works best for you and your health goals.

• #15 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD. […] Other dietary components can also be beneficial in the treatment of NAFLD, like changes in Vitamin E, caffeine and polyphenol intake.

• #16 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD. […] Other dietary components can also be beneficial in the treatment of NAFLD, like changes in Vitamin E, caffeine and polyphenol intake.

• #17 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD. […] Other dietary components can also be beneficial in the treatment of NAFLD, like changes in Vitamin E, caffeine and polyphenol intake.

• #18 Fatty liver disease: What it is and what to do about it – Harvard Health

  https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746

  The good news is that the most effective treatment so far for fatty liver disease does not involve medications, but rather lifestyle changes. The bad news is that these are typically hard to achieve and maintain for many people. Here’s what we know helps: […] Weight loss of roughly 5% of your body weight might be enough to improve abnormal liver tests and decrease the fat in the liver. Losing between 7% and 10% of body weight seems to decrease the amount of inflammation and injury to liver cells, and it may even reverse some of the damage of fibrosis. […] It appears that aerobic exercise also leads to decreased fat in the liver, and with vigorous intensity, possibly also decreased inflammation independent of weight loss. […] Some studies suggest that the Mediterranean diet may also decrease the fat in the liver. […] Some studies showed that patients with NAFLD who drank coffee (about two cups every day) had a decreased risk in fibrosis.

• #19 What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

  https://www.mdpi.com/2077-0383/12/5/1852

  The positive impact of MED can be obtained even without calorie intake or body mass reductions. […] The protein content in a diet, in addition to the hypocaloric diet and its impact on liver fat reduction, was the subject of research conducted by Xu et al. […] It also was proven that a whole-grain diet has beneficial effects, including hepatic enzyme decrease and the improvement of liver steatosis. […] Regarding the dietary treatment approach of NAFLD, we can also specify the American Heart Association (AHA) and Fatty Liver in Obesity (FliO) hypocaloric diets. […] In response to the complications posed by NAFLD, researchers are searching for alternative solutions to address this problem. […] It has been proven that omega-3 supplementation has beneficial effects on patients with NAFLD.

• #20 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant. […] Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #21 Non-alcoholic fatty liver disease (NAFLD) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/non-alcoholic-fatty-liver-disease-nafld/

  Exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week. All types of exercise can help improve NAFLD, even if you dont lose weight. […] Stop smoking if you smoke, stopping can help reduce your risk of problems such as heart attacks and strokes. […] NAFLD isnt caused by alcohol, but drinking may make the condition worse. Its therefore advisable to cut down or stop drinking alcohol. […] There isnt currently any medication that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medication to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and/or treat obesity. […] If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant.

• #22 Fatty liver disease: What it is and what to do about it – Harvard Health

  https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746

  The good news is that the most effective treatment so far for fatty liver disease does not involve medications, but rather lifestyle changes. The bad news is that these are typically hard to achieve and maintain for many people. Here’s what we know helps: […] Weight loss of roughly 5% of your body weight might be enough to improve abnormal liver tests and decrease the fat in the liver. Losing between 7% and 10% of body weight seems to decrease the amount of inflammation and injury to liver cells, and it may even reverse some of the damage of fibrosis. […] It appears that aerobic exercise also leads to decreased fat in the liver, and with vigorous intensity, possibly also decreased inflammation independent of weight loss. […] Some studies suggest that the Mediterranean diet may also decrease the fat in the liver. […] Some studies showed that patients with NAFLD who drank coffee (about two cups every day) had a decreased risk in fibrosis.

• #23 Non-alcoholic fatty liver disease (NAFLD) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/non-alcoholic-fatty-liver-disease-nafld/

  Exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week. All types of exercise can help improve NAFLD, even if you dont lose weight. […] Stop smoking if you smoke, stopping can help reduce your risk of problems such as heart attacks and strokes. […] NAFLD isnt caused by alcohol, but drinking may make the condition worse. Its therefore advisable to cut down or stop drinking alcohol. […] There isnt currently any medication that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medication to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and/or treat obesity. […] If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant.

• #24 Non-alcoholic Fatty Liver Disease: Causes and Diagnoses

  https://patient.info/healthy-living/alcohol-and-liver-disease/non-alcoholic-fatty-liver-disease

  If you are obese or overweight, the main treatment advised for NAFLD is usually gradual weight loss and regular exercise. This not only helps with NAFLD, but will help reduce your risk of developing cardiovascular problems. […] Most cases of NAFLD are linked to being obese or overweight. There is good evidence that a programme of gradual weight loss and regular exercise can reduce the amount of fat in your liver. So, if you have simple fatty liver or mild NASH, this may prevent or delay the progression of NAFLD. It may reduce your chance of developing cirrhosis – a condition where normal liver tissue is replaced by a lot of scar tissue (fibrosis). […] Aerobic exercise and diet changes are the most effective way to manage NAFLD. Try to aim for 150-200 minutes of moderate-intensity exercise a week – split over 3-5 sessions. It’s a good idea to drink water instead of sugary drinks. Switching to a Mediterranean diet can reduce liver fat, even if you don’t lose weight.

• #25 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Nonalcoholic fatty liver disease (NAFLD), the most common chronic hepatic disease, has become a leading health problem worldwide. The present review summarized the methods and mechanisms to treat NAFLD, including the Mediterranean diet, physical activity and exercise, bariatric surgery and specific therapeutic agents, including statins, peroxisome proliferatoractivated receptor agonists, cenicriviroc and farnesoid X receptor agonists. […] At present, there is no approved pharmacological treatment for NAFLD. In the present review, the current proposed treatments for NAFLD are summarized under the categories of lifestyle, bioactive compounds and medicines. […] It is well established that the risk of hepatic steatosis increases after consuming high-calorie, high-sugar and high-fat foods. A notable reduction in NAFLD activity score, remission of steatohepatitis and regression of fibrosis were noted in patients with weight loss and diet alteration. In addition, patients with NAFLD are advised to consume the Mediterranean diet in the European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity Clinical Practice Guidelines for the management of NAFLD.

• #26 Treatment Options and Continuity of Care in MAFLD

  https://www.ecrjournal.com/articles/treatment-options-and-continuity-care-metabolic-associated-fatty-liver-disease?language_content_entity=en

  Current clinical practice guidelines agree that the cornerstone of MASLD treatment in obese/overweight patients is a lifestyle intervention involving changes in diet and physical activity, aiming for a weight reduction of 7-10% and a calorie reduction of 500-1,000 kcal/day. […] Evidence suggests that calorie restriction can improve numerous metabolic parameters beyond its effect on liver-related outcomes. […] The Mediterranean diet is the only diet recommended as a potential therapy for MASLD by several scientific societies: the European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of Obesity. […] Although weight loss is the main goal, several systematic reviews have shown that exercise even at low level, without associated weight loss, can reduce intrahepatic lipid (IHL).

• #27 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] Demonstration of these changes in a proportion of patients after just one year of treatment is notable, as the disease typically progresses slowly with a majority of patients taking years or even decades to show progression.

• #28 MASLD, NAFLD and fatty liver disease – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/masld-nafld-and-fatty-liver-disease/

  There are currently no medicines available in the UK to specifically treat MASLD. But there is a lot of research being done to develop some. […] Whatever your weight, eating healthily and being more physically active can each help reduce liver fat and improve fatty liver disease. […] If you are overweight, the most important thing you can do to improve your condition is to lose weight. Research shows that losing 5 to 10% of your body weight can control and in some cases reverse MASLD. […] The aim is to generally eat and drink healthily most of the time and not have too much or too little of anything. […] Aim to do at least 2 hours of physical activity every week that gets you a bit out of breath.

• #29 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] Demonstration of these changes in a proportion of patients after just one year of treatment is notable, as the disease typically progresses slowly with a majority of patients taking years or even decades to show progression.

• #30 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] Demonstration of these changes in a proportion of patients after just one year of treatment is notable, as the disease typically progresses slowly with a majority of patients taking years or even decades to show progression.

• #31 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] Demonstration of these changes in a proportion of patients after just one year of treatment is notable, as the disease typically progresses slowly with a majority of patients taking years or even decades to show progression.

• #32 Fatty Liver Disease: Nonalcoholic and Alcoholic Steatohepatitis (NAFLD/AFLD)

  https://www.webmd.com/fatty-liver-disease/fatty-liver-disease

  Usually the first line of treatment is to lose excess weight. It helps reduce fat, inflammation, and scarring in your liver. Losing just 3% to 5% of your body weight can cut down on how much fat is in your liver. Weight loss surgery is also an option if you do not achieve the weight loss goal after lifestyle interventions. […] One drug, remetirom (Rezdiffra), has been approved to treat MASH. You use it as part of a treatment plan that includes exercise and a healthy diet to lose weight. […] And whether you have MASLD or ALD, you’ll also need to not drink alcohol. You may be able to undo some of the liver damage that’s already happened. If you need to, talk to your doctor about how you can get help. You may need a medically supervised detox program to safely quit drinking and manage withdrawal symptoms.

• #33 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] Demonstration of these changes in a proportion of patients after just one year of treatment is notable, as the disease typically progresses slowly with a majority of patients taking years or even decades to show progression.

• #34 FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease > News > Yale Medicine

  https://www.yalemedicine.org/news/rezdiffra-for-nash-nonalcoholic-steatohepatitis

  Results from an ongoing Phase III clinical trial were published in The New England Journal of Medicine. Resmetirom, which was tested at two dose strengths, was shown to resolve NASH without a worsening of fibrosis in 26% (at the lower dose) and 30% (at the higher dose) of patients compared to 10% in the placebo group. The trial also showed that the drug improved fibrosis by at least one stage in 24% (at the lower dose) and 26% (at the higher dose) of the patients, compared to 14% in the placebo group. […] Anti-obesity medications, such as semaglutide (Wegovy) and tirzepatide (Zepound), can help treat fatty liver disease and potentially stop it from advancing to NASH, but once someone has NASH, these drugs have not yet been proven to reverse it, Dr. Mehal says. However, clinical trials are ongoing, and the early data is very encouraging that these medications will be effective for NASH, he adds. […] Rezdiffra is meant for adults with NASH who have well-developed, but not extremely severe scarring in their liver, and it should be used along with a healthy diet and an active lifestyle, says Dr. Mehal.

• #35 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Use of Rezdiffra should be avoided in patients with decompensated cirrhosis. Patients should stop using Rezdiffra if they develop signs or symptoms of worsening liver function while on Rezdiffra treatment. […] The FDA approved Rezdiffra under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and address an unmet medical need, based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.

• #36 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #37 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #38 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  Three Cochrane reviews found insufficient evidence to support the use of bile acids (e.g., ursodeoxycholic acid), antioxidant supplements, metformin (Glucophage), or thiazolidinediones in the absence of diabetes in patients with nonalcoholic fatty liver disease. Another meta-analysis of 49 randomized controlled trials found that thiazolidinediones (especially pioglitazone [Actos]) improved steatosis and inflammation but were associated with a weight increase of 4.5 to 11 lb (2 to 5 kg) in 66% to 75% of patients and edema in 4% to 10% of patients. This meta-analysis also found conflicting and heterogenous results for metformin, simvastatin (Zocor), antioxidants, pentoxifylline (Trental), telmisartan (Micardis), and l-carnitine. A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #39 Natural Remedies for Fatty Liver Disease

  https://www.healthline.com/health/home-remedies-for-fatty-liver

  Certain substances can put excess stress on your liver. […] According to research from 2019, even moderate consumption of alcohol can lead to disease progression in individuals with NAFLD. […] Vitamin E is one antioxidant that may reduce inflammation caused by NAFLD. […] The AASLD recommends a daily dose of 800 international units of vitamin E per day for people with NAFLD who don’t have diabetes and have confirmed nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD. […] There are currently no approved medical treatments for NAFLD, though there are some in development. […] One such treatment is pioglitazone, a medication typically prescribed for type 2 diabetes. […] More research needs to be done to understand the long-term safety and effectiveness of this treatment. […] Lifestyle and dietary changes are currently the most effective options for managing NAFLD. […] If you have this condition, be sure to work closely with your doctor to develop a personalized treatment plan that’s right for you.

• #40 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  Three Cochrane reviews found insufficient evidence to support the use of bile acids (e.g., ursodeoxycholic acid), antioxidant supplements, metformin (Glucophage), or thiazolidinediones in the absence of diabetes in patients with nonalcoholic fatty liver disease. Another meta-analysis of 49 randomized controlled trials found that thiazolidinediones (especially pioglitazone [Actos]) improved steatosis and inflammation but were associated with a weight increase of 4.5 to 11 lb (2 to 5 kg) in 66% to 75% of patients and edema in 4% to 10% of patients. This meta-analysis also found conflicting and heterogenous results for metformin, simvastatin (Zocor), antioxidants, pentoxifylline (Trental), telmisartan (Micardis), and l-carnitine. A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #41 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  For patients with biopsy-proven NASH, where lifestyle intervention has failed, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered. […] Several studies have demonstrated benefit from the thiazolidinediones in patients with NASH both with and without diabetes. […] A recent meta-analysis has demonstrated that pioglitazone treatment in NASH significantly improves steatosis, inflammation and to a lesser degree, fibrosis. […] Vitamin E is an antioxidant that has recently been shown to have beneficial effects on histology in non-diabetic patients with NASH. […] Although vitamin E looks like a promising treatment for NASH, there are concerns about the long-term effects of vitamin E with a meta-analysis showing a small overall increase in all-cause mortality at doses 400IU/day. […] Therefore, it should currently be reserved for selected patients with more advanced pre-cirrhotic NASH who have failed lifestyle interventions.

• #42 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #43 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Omega-3 fatty acids may be considered for hypertriglyceridemia in patients with NAFLD, but it is premature to recommend them for the specific treatment of NAFLD or NASH. The 2023 AASLD guidelines also recommend lifestyle changes and supplementation with omega-3 fatty acids, icosapent ethyl, or fibrates. […] – Metformin is not recommended as a specific treatment for liver disease in adults with NASH. […] – Semaglutide can be considered for its approved indications (type 2 diabetes, obesity) in those with NASH (cardiovascular benefit, improves NASH). Similarly, pioglitazone improves NASH and can be considered in those with NASH and type 2 diabetes. […] – Pioglitazone may be used to treat steatohepatitis in both patients with and without type 2 diabetes with biopsy-proven NASH, but the risks and benefits should be thoroughly discussed with the patient prior to initiation of treatment.

• #44 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  Three Cochrane reviews found insufficient evidence to support the use of bile acids (e.g., ursodeoxycholic acid), antioxidant supplements, metformin (Glucophage), or thiazolidinediones in the absence of diabetes in patients with nonalcoholic fatty liver disease. Another meta-analysis of 49 randomized controlled trials found that thiazolidinediones (especially pioglitazone [Actos]) improved steatosis and inflammation but were associated with a weight increase of 4.5 to 11 lb (2 to 5 kg) in 66% to 75% of patients and edema in 4% to 10% of patients. This meta-analysis also found conflicting and heterogenous results for metformin, simvastatin (Zocor), antioxidants, pentoxifylline (Trental), telmisartan (Micardis), and l-carnitine. A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #45 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  For patients with biopsy-proven NASH, where lifestyle intervention has failed, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered. […] Several studies have demonstrated benefit from the thiazolidinediones in patients with NASH both with and without diabetes. […] A recent meta-analysis has demonstrated that pioglitazone treatment in NASH significantly improves steatosis, inflammation and to a lesser degree, fibrosis. […] Vitamin E is an antioxidant that has recently been shown to have beneficial effects on histology in non-diabetic patients with NASH. […] Although vitamin E looks like a promising treatment for NASH, there are concerns about the long-term effects of vitamin E with a meta-analysis showing a small overall increase in all-cause mortality at doses 400IU/day. […] Therefore, it should currently be reserved for selected patients with more advanced pre-cirrhotic NASH who have failed lifestyle interventions.

• #46 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  The present therapies under evaluation for NAFLD target the various stages of disease, with some having the possibility of reversing underlying fibrosis. Below we categorize therapies based on their role in the pathophysiological process of NAFLD. […] Since insulin resistance is one of the main drivers of NAFLD, obesity, and T2DM, and these diseases often coexist in the same patient, there have been several clinical trials to assess the efficacy of antidiabetic therapies. Currently, semaglutide and dapagliflozin are under phase 3 trials. […] One promising therapy are GLP-1 receptor agonists (GLP-1RA), which stimulate fatty acid oxidation and gluconeogenesis, cause weight loss in diabetic and non-diabetic patients, improve glycemic control in patients with diabetes, and are associated with decreased cardiovascular risk.

• #47 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  The present therapies under evaluation for NAFLD target the various stages of disease, with some having the possibility of reversing underlying fibrosis. Below we categorize therapies based on their role in the pathophysiological process of NAFLD. […] Since insulin resistance is one of the main drivers of NAFLD, obesity, and T2DM, and these diseases often coexist in the same patient, there have been several clinical trials to assess the efficacy of antidiabetic therapies. Currently, semaglutide and dapagliflozin are under phase 3 trials. […] One promising therapy are GLP-1 receptor agonists (GLP-1RA), which stimulate fatty acid oxidation and gluconeogenesis, cause weight loss in diabetic and non-diabetic patients, improve glycemic control in patients with diabetes, and are associated with decreased cardiovascular risk.

• #48 FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease > News > Yale Medicine

  https://www.yalemedicine.org/news/rezdiffra-for-nash-nonalcoholic-steatohepatitis

  Results from an ongoing Phase III clinical trial were published in The New England Journal of Medicine. Resmetirom, which was tested at two dose strengths, was shown to resolve NASH without a worsening of fibrosis in 26% (at the lower dose) and 30% (at the higher dose) of patients compared to 10% in the placebo group. The trial also showed that the drug improved fibrosis by at least one stage in 24% (at the lower dose) and 26% (at the higher dose) of the patients, compared to 14% in the placebo group. […] Anti-obesity medications, such as semaglutide (Wegovy) and tirzepatide (Zepound), can help treat fatty liver disease and potentially stop it from advancing to NASH, but once someone has NASH, these drugs have not yet been proven to reverse it, Dr. Mehal says. However, clinical trials are ongoing, and the early data is very encouraging that these medications will be effective for NASH, he adds. […] Rezdiffra is meant for adults with NASH who have well-developed, but not extremely severe scarring in their liver, and it should be used along with a healthy diet and an active lifestyle, says Dr. Mehal.

• #49 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #50 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Omega-3 fatty acids may be considered for hypertriglyceridemia in patients with NAFLD, but it is premature to recommend them for the specific treatment of NAFLD or NASH. The 2023 AASLD guidelines also recommend lifestyle changes and supplementation with omega-3 fatty acids, icosapent ethyl, or fibrates. […] – Metformin is not recommended as a specific treatment for liver disease in adults with NASH. […] – Semaglutide can be considered for its approved indications (type 2 diabetes, obesity) in those with NASH (cardiovascular benefit, improves NASH). Similarly, pioglitazone improves NASH and can be considered in those with NASH and type 2 diabetes. […] – Pioglitazone may be used to treat steatohepatitis in both patients with and without type 2 diabetes with biopsy-proven NASH, but the risks and benefits should be thoroughly discussed with the patient prior to initiation of treatment.

• #51 Patient-Centered Management of Nonalcoholic Fatty Liver Disease

  https://www.uspharmacist.com/article/patientcentered-management-of-nonalcoholic-fatty-liver-disease

  The AASLD recommendation is first and foremost weight loss either with diet alone or with exercise. This recommendation is also in line with its guidelines for other disease states. A study published in 2010 by Promrat et al demonstrated the efficacy of weight loss with a goal of 7% to 10% in treatment-arm patients with an outcome of improved liver histology in NASH. […] The AASLD recommends vitamin E at a daily dose of 800 IU/day as first-line therapy in nondiabetic adults with biopsy-proven NASH, as it has been shown to improve liver histology in this population. […] The AASLD recommends use of pioglitazone to treat steatohepatitis in patients with biopsy-proven NASH; however, long-term efficacy is not known. […] The current AASLD guidelines do not recommend metformin for treatment of NAFLD specifically. Treatment with metformin, however, may be beneficial in patients who have previously been diagnosed with type 2 diabetes, as it would already be in use to improve insulin sensitivity.

• #52 Treatment regimens for non-alcoholic fatty liver disease | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-treatment-regimens-for-non-alcoholic-fatty-S1665268119318277

  Treatment regimens for non-alcoholic fatty liver disease […] With the growing epidemic of obesity and diabetes, more attention has been placed on metabolic syndrome and its associated hepatic manifestation, non-alcoholic fatty liver disease (NAFLD). Current treatment recommendations include weight loss and the reversal of other components of metabolic syndrome, but several other treatment modalities are under investigation. To date, no pharmacologic treatment has been reliably shown to be effective for NASH. This article reviews all available treatment modalities, including lifestyle changes, bariatric surgery, weight loss medications, insulin sensitizers, lipid lowering agents, antioxidants, cytoprotective agents, and other novel treatments. […] Patients with NAFLD or metabolic syndrome are encouraged to adopt a program of diet and exercise with the goal of weight loss as a first step in their treatment. The medications orlistat and sibutramine are used for the treatment of obesity and have been studied for their effects on steatohepatitis. Most of the work on histological improvement after weight loss relies on patients who have had bariatric surgery. Among the insulin sensitizing agents used for the treatment of NASH, thiazolidinediones (TZDs) have been studied the most and have shown the most favorable results. Several studies have examined the utility of metformin in the management of NAFLD and NASH. Interest in the use of antihyperlipidemic agents for NAFLD stems from the role of dyslipidemia in metabolic syndrome and its association with NAFLD. Oxidative stress is considered a major contributor as the second hit in the pathogenesis of NAFLD and NASH, justifying the study of several antioxidants in NAFLD treatment. Several studies have examined the effects of ursodeoxycholic acid (UDCA) in NAFLD and NASH patients. Other potential components targeting the second hit in the pathogenesis of NAFLD include those agents improving necrosis, inflammation, and fibrogenesis caused by a number of pro-inflammatory adipocytokines, including tumor necrosis factor alpha (TNF-). Attempts to find other safe and efficacious treatments for NAFLD and NASH include investigations of the angiotensin receptor blockers (ARB) telmisartan and irbesartan.

• #53 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  There is no definitive pharmacologic therapy approved for treatment of nonalcoholic fatty liver disease (NAFLD). However, in the appropriate clinical setting, consider medications approved to treat the associated comorbidities that have potential benefit in NAFLD. Thus, management of NAFLD should include treating the associated obesity, hyperlipidemia, insulin resistance, and type 2 diabetes. […] The American Association for the Study of Liver Diseases (AASLD) indicates that statins are safe and recommended to lower the risk of cardiovascular disease in those with conditions across the NAFLD spectrum, including compensated cirrhosis. However, for patients with decompensated cirrhosis, there are only limited data regarding the safety and efficacy of statins, although use of these agents could be considered in populations at high CVD risk along with close monitoring.

• #54 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Glucagon-like peptide (GLP)-1 agonists have been studied to treat liver disease in patients with NAFLD or NASH; however, it is still premature to consider these agents as treatment options at this time. […] – Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy). […] – Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] – Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #55 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Glucagon-like peptide (GLP)-1 agonists have been studied to treat liver disease in patients with NAFLD or NASH; however, it is still premature to consider these agents as treatment options at this time. […] – Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy). […] – Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] – Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #56 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Glucagon-like peptide (GLP)-1 agonists have been studied to treat liver disease in patients with NAFLD or NASH; however, it is still premature to consider these agents as treatment options at this time. […] – Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy). […] – Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] – Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #57 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Omega-3 fatty acids may be considered for hypertriglyceridemia in patients with NAFLD, but it is premature to recommend them for the specific treatment of NAFLD or NASH. The 2023 AASLD guidelines also recommend lifestyle changes and supplementation with omega-3 fatty acids, icosapent ethyl, or fibrates. […] – Metformin is not recommended as a specific treatment for liver disease in adults with NASH. […] – Semaglutide can be considered for its approved indications (type 2 diabetes, obesity) in those with NASH (cardiovascular benefit, improves NASH). Similarly, pioglitazone improves NASH and can be considered in those with NASH and type 2 diabetes. […] – Pioglitazone may be used to treat steatohepatitis in both patients with and without type 2 diabetes with biopsy-proven NASH, but the risks and benefits should be thoroughly discussed with the patient prior to initiation of treatment.

• #58 Patient-Centered Management of Nonalcoholic Fatty Liver Disease

  https://www.uspharmacist.com/article/patientcentered-management-of-nonalcoholic-fatty-liver-disease

  Several studies have investigated the use of omega-3 fatty acids in NAFLD for showing possible benefit; however, the results were limited by small sample size and methodological flaws. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH, but they may be considered as the first-line agents to treat hypertriglyceridemia in patients with NAFLD. […] Statins are an important class of agents to treat dyslipidemia, and yet there often is resistance to using statins in patients with suspected or established chronic liver disease, including NAFLD and NASH. Given the lack of evidence to show that patients with NAFLD and NASH are at increased risk for serious drug-induced liver injury from statins, these agents should not be avoided in patients with NAFLD and NASH.

• #59 Natural Remedies for Fatty Liver Disease

  https://www.healthline.com/health/home-remedies-for-fatty-liver

  According to research, coffee offers a number of protective benefits for the liver. […] The same research reported that among people with NAFLD, regular coffee consumption reduces overall liver damage. […] According to research from 2017, NAFLD is often associated with a sedentary lifestyle. […] It’s important to stay active when you have NAFLD. […] Dietary sugars such as fructose and sucrose have been linked to the development of NAFLD. […] According to research, NAFLD can make it harder for your body to manage cholesterol on its own. […] Try to limit your intake of certain types of fats to help manage your cholesterol and treat NAFLD. […] Omega-3 fatty acids are polyunsaturated fats found in foods such as oily fish and some nuts and seeds. […] Research suggests that taking an omega-3 supplement may reduce liver fat and improve cholesterol levels.

• #60 Patient-Centered Management of Nonalcoholic Fatty Liver Disease

  https://www.uspharmacist.com/article/patientcentered-management-of-nonalcoholic-fatty-liver-disease

  Several studies have investigated the use of omega-3 fatty acids in NAFLD for showing possible benefit; however, the results were limited by small sample size and methodological flaws. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH, but they may be considered as the first-line agents to treat hypertriglyceridemia in patients with NAFLD. […] Statins are an important class of agents to treat dyslipidemia, and yet there often is resistance to using statins in patients with suspected or established chronic liver disease, including NAFLD and NASH. Given the lack of evidence to show that patients with NAFLD and NASH are at increased risk for serious drug-induced liver injury from statins, these agents should not be avoided in patients with NAFLD and NASH.

• #61 The best medications for fatty liver: Research and FAQs

  https://www.medicalnewstoday.com/articles/best-medication-for-fatty-liver

  Lifestyle changes are the primary treatment for fatty liver disease. However, medications including insulin sensitizers and lipid-lowering drugs can help to treat the disease. […] Lifestyle changes, including the pursuit of weight loss, are the main treatment approach doctors recommend for NAFLD. However, the following medications may also be effective against fatty liver disease: […] Insulin resistance plays an important role in the development and progression of NAFLD. The results of randomized controlled trials suggest that insulin sensitizers also called thiazolidinediones (TZDs) are effective against NASH. […] Lipid-lowering drugs help inhibit the production of cholesterol. Initial studies suggest that lipid-lowering drugs such as statins could be helpful in treating NAFLD. […] Randomized controlled trials have also suggested that the lipid-lowering drug ezetimibe may be effective for the treatment of fatty liver disease.

• #62 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #63 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #64 The best medications for fatty liver: Research and FAQs

  https://www.medicalnewstoday.com/articles/best-medication-for-fatty-liver

  Pentoxifylline may inhibit the progression of NAFLD. However, it can cause adverse effects such as nausea and vomiting. […] Several clinical trials have suggested that angiotensin II type 1 blockers may be effective in inhibiting the progression of NASH. […] Corticosteroids may be effective in the treatment of alcoholic fatty liver disease. […] Current treatment options for fatty liver disease include: […] A 2020 review indicates that vitamin E supplementation may also help treat NAFLD in adults. […] Bariatric surgery may help improve NAFLD in people with obesity. […] Liver transplantation is the only option for people with liver failure. […] Early diagnosis and treatment can help reverse fatty liver disease. […] No medications are currently approved for the treatment of fatty liver disease. […] Currently, doctors recommend diet and lifestyle changes, including the pursuit of weight loss, to help manage fatty liver disease in the early stages. They may recommend surgery or liver transplantation for people with serious liver damage or liver failure.

• #65 The best medications for fatty liver: Research and FAQs

  https://www.medicalnewstoday.com/articles/best-medication-for-fatty-liver

  Pentoxifylline may inhibit the progression of NAFLD. However, it can cause adverse effects such as nausea and vomiting. […] Several clinical trials have suggested that angiotensin II type 1 blockers may be effective in inhibiting the progression of NASH. […] Corticosteroids may be effective in the treatment of alcoholic fatty liver disease. […] Current treatment options for fatty liver disease include: […] A 2020 review indicates that vitamin E supplementation may also help treat NAFLD in adults. […] Bariatric surgery may help improve NAFLD in people with obesity. […] Liver transplantation is the only option for people with liver failure. […] Early diagnosis and treatment can help reverse fatty liver disease. […] No medications are currently approved for the treatment of fatty liver disease. […] Currently, doctors recommend diet and lifestyle changes, including the pursuit of weight loss, to help manage fatty liver disease in the early stages. They may recommend surgery or liver transplantation for people with serious liver damage or liver failure.

• #66 Treatment regimens for non-alcoholic fatty liver disease | Annals of Hepatology

  https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-treatment-regimens-for-non-alcoholic-fatty-S1665268119318277

  Treatment regimens for non-alcoholic fatty liver disease […] With the growing epidemic of obesity and diabetes, more attention has been placed on metabolic syndrome and its associated hepatic manifestation, non-alcoholic fatty liver disease (NAFLD). Current treatment recommendations include weight loss and the reversal of other components of metabolic syndrome, but several other treatment modalities are under investigation. To date, no pharmacologic treatment has been reliably shown to be effective for NASH. This article reviews all available treatment modalities, including lifestyle changes, bariatric surgery, weight loss medications, insulin sensitizers, lipid lowering agents, antioxidants, cytoprotective agents, and other novel treatments. […] Patients with NAFLD or metabolic syndrome are encouraged to adopt a program of diet and exercise with the goal of weight loss as a first step in their treatment. The medications orlistat and sibutramine are used for the treatment of obesity and have been studied for their effects on steatohepatitis. Most of the work on histological improvement after weight loss relies on patients who have had bariatric surgery. Among the insulin sensitizing agents used for the treatment of NASH, thiazolidinediones (TZDs) have been studied the most and have shown the most favorable results. Several studies have examined the utility of metformin in the management of NAFLD and NASH. Interest in the use of antihyperlipidemic agents for NAFLD stems from the role of dyslipidemia in metabolic syndrome and its association with NAFLD. Oxidative stress is considered a major contributor as the second hit in the pathogenesis of NAFLD and NASH, justifying the study of several antioxidants in NAFLD treatment. Several studies have examined the effects of ursodeoxycholic acid (UDCA) in NAFLD and NASH patients. Other potential components targeting the second hit in the pathogenesis of NAFLD include those agents improving necrosis, inflammation, and fibrogenesis caused by a number of pro-inflammatory adipocytokines, including tumor necrosis factor alpha (TNF-). Attempts to find other safe and efficacious treatments for NAFLD and NASH include investigations of the angiotensin receptor blockers (ARB) telmisartan and irbesartan.

• #67 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Glucagon-like peptide (GLP)-1 agonists have been studied to treat liver disease in patients with NAFLD or NASH; however, it is still premature to consider these agents as treatment options at this time. […] – Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy). […] – Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] – Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #68 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Exercise notably decreases steatosis and the risk of NAFLD developing into NASH. […] Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are the most common means of bariatric surgery that aim to shrink the stomach. The mechanisms by which they attenuate NAFLD appear to be reduction of oxidative stress and inflammation. […] Biologically active substances, which are cheaper and have fewer side effects, are attractive treatment methods for NAFLD. […] Statins are mainly used to prevent cardiovascular disease and decrease LDL-cholesterol levels. An increasing number of studies suggested that statins were useful to reduce the risk of NAFLD. […] PPAR agonists are traditionally used for treating MetS by lowering TG and glucose levels. […] Cenicriviroc is an oral and dual antagonist of CCR2 and CCR5. It exerted anti-inflammatory and antifibrotic effects in a diet-induced NAFLD mouse model and weakened NAFLD. […] In the present review, the roles of the Mediterranean diet, exercise, bariatric surgery, drugs and biologically active substances in the intervention of NAFLD were summarized, with the aim that this will aid clinical research and disease treatment.

• #69 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #70 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  – Glucagon-like peptide (GLP)-1 agonists have been studied to treat liver disease in patients with NAFLD or NASH; however, it is still premature to consider these agents as treatment options at this time. […] – Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy). […] – Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] – Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #71 Fatty liver disease – Wikipedia

  https://en.wikipedia.org/wiki/Fatty_liver_disease

  Treatment of NAFLD is generally by dietary changes and exercise to bring about weight loss. […] In those who are severely affected, liver transplantation may be an option. […] Decreasing caloric intake by at least 30% or by approximately 750-1,000 kcal/day results in improvement in hepatic steatosis. […] For people with NAFLD or NASH, weight loss via a combination of diet and exercise was shown to improve or resolve the disease. […] In more serious cases, medications that decrease insulin resistance, hyperlipidemia, and those that induce weight loss such as bariatric surgery as well as vitamin E have been shown to improve or resolve liver function. […] Bariatric surgery, while not recommended in 2017 as a treatment for FLD alone, has been shown to revert FLD, NAFLD, NASH and advanced steatohepatitis in over 90% of people who have undergone this surgery for the treatment of obesity. […] In the case of long-term total-parenteral-nutrition-induced fatty liver disease, choline has been shown to alleviate symptoms.

• #72 Fatty liver disease – Wikipedia

  https://en.wikipedia.org/wiki/Fatty_liver_disease

  Treatment of NAFLD is generally by dietary changes and exercise to bring about weight loss. […] In those who are severely affected, liver transplantation may be an option. […] Decreasing caloric intake by at least 30% or by approximately 750-1,000 kcal/day results in improvement in hepatic steatosis. […] For people with NAFLD or NASH, weight loss via a combination of diet and exercise was shown to improve or resolve the disease. […] In more serious cases, medications that decrease insulin resistance, hyperlipidemia, and those that induce weight loss such as bariatric surgery as well as vitamin E have been shown to improve or resolve liver function. […] Bariatric surgery, while not recommended in 2017 as a treatment for FLD alone, has been shown to revert FLD, NAFLD, NASH and advanced steatohepatitis in over 90% of people who have undergone this surgery for the treatment of obesity. […] In the case of long-term total-parenteral-nutrition-induced fatty liver disease, choline has been shown to alleviate symptoms.

• #73 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Exercise notably decreases steatosis and the risk of NAFLD developing into NASH. […] Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are the most common means of bariatric surgery that aim to shrink the stomach. The mechanisms by which they attenuate NAFLD appear to be reduction of oxidative stress and inflammation. […] Biologically active substances, which are cheaper and have fewer side effects, are attractive treatment methods for NAFLD. […] Statins are mainly used to prevent cardiovascular disease and decrease LDL-cholesterol levels. An increasing number of studies suggested that statins were useful to reduce the risk of NAFLD. […] PPAR agonists are traditionally used for treating MetS by lowering TG and glucose levels. […] Cenicriviroc is an oral and dual antagonist of CCR2 and CCR5. It exerted anti-inflammatory and antifibrotic effects in a diet-induced NAFLD mouse model and weakened NAFLD. […] In the present review, the roles of the Mediterranean diet, exercise, bariatric surgery, drugs and biologically active substances in the intervention of NAFLD were summarized, with the aim that this will aid clinical research and disease treatment.

• #74 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Exercise notably decreases steatosis and the risk of NAFLD developing into NASH. […] Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are the most common means of bariatric surgery that aim to shrink the stomach. The mechanisms by which they attenuate NAFLD appear to be reduction of oxidative stress and inflammation. […] Biologically active substances, which are cheaper and have fewer side effects, are attractive treatment methods for NAFLD. […] Statins are mainly used to prevent cardiovascular disease and decrease LDL-cholesterol levels. An increasing number of studies suggested that statins were useful to reduce the risk of NAFLD. […] PPAR agonists are traditionally used for treating MetS by lowering TG and glucose levels. […] Cenicriviroc is an oral and dual antagonist of CCR2 and CCR5. It exerted anti-inflammatory and antifibrotic effects in a diet-induced NAFLD mouse model and weakened NAFLD. […] In the present review, the roles of the Mediterranean diet, exercise, bariatric surgery, drugs and biologically active substances in the intervention of NAFLD were summarized, with the aim that this will aid clinical research and disease treatment.

• #75 Non-Alcoholic Fatty Liver Treatment – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/nafl/treatment.asp

  Intensive lifestyle intervention with 7% weight loss diminishes liver inflammation; 10% weight loss can decrease liver fibrosis. Motivational interviewing to engage patient to create their preferred plan, cognitive behavioral therapy, weight loss, diet, and exercise provide the most enduring benefit. For more on motivational interviewing for NAFLD, please see our video and pocket guide for providers. […] Bariatric surgery for patients who meet criteria (e.g., 40 kg/m2 or 35 with comorbidity [e.g., diabetes, HTN]). […] Weight loss pharmacotherapy can help patients with NAFLD achieve weight loss. […] Future NAFLD therapies are promising but not yet FDA approved.

• #76 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  Bariatric and metabolic surgery results in resolution of NAFLD/NASH in the majority of the patients (64.2% in patients that underwent Roux-Y Gastric Bypass (RYGB) and 5.5% in Sleeve Gastrectomy (SG)). […] A meta-analysis on 48 studies showed that the combination of pioglitazone and Roux-en Y Gastric Bypass surgery had the best effects on the NAFLD Activity Score.

• #77 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  Bariatric and metabolic surgery results in resolution of NAFLD/NASH in the majority of the patients (64.2% in patients that underwent Roux-Y Gastric Bypass (RYGB) and 5.5% in Sleeve Gastrectomy (SG)). […] A meta-analysis on 48 studies showed that the combination of pioglitazone and Roux-en Y Gastric Bypass surgery had the best effects on the NAFLD Activity Score.

• #78 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant. […] Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #79 The best medications for fatty liver: Research and FAQs

  https://www.medicalnewstoday.com/articles/best-medication-for-fatty-liver

  Pentoxifylline may inhibit the progression of NAFLD. However, it can cause adverse effects such as nausea and vomiting. […] Several clinical trials have suggested that angiotensin II type 1 blockers may be effective in inhibiting the progression of NASH. […] Corticosteroids may be effective in the treatment of alcoholic fatty liver disease. […] Current treatment options for fatty liver disease include: […] A 2020 review indicates that vitamin E supplementation may also help treat NAFLD in adults. […] Bariatric surgery may help improve NAFLD in people with obesity. […] Liver transplantation is the only option for people with liver failure. […] Early diagnosis and treatment can help reverse fatty liver disease. […] No medications are currently approved for the treatment of fatty liver disease. […] Currently, doctors recommend diet and lifestyle changes, including the pursuit of weight loss, to help manage fatty liver disease in the early stages. They may recommend surgery or liver transplantation for people with serious liver damage or liver failure.

• #80 Fatty Liver Disease: Nonalcoholic and Alcoholic Steatohepatitis (NAFLD/AFLD)

  https://www.webmd.com/fatty-liver-disease/fatty-liver-disease

  If you have complications due to either type of FLD, such as cirrhosis or liver failure, you may need to have a liver transplant. In general, people with MASH who get a liver transplant do very well. […] FLD can be reversed if you avoid alcohol and take steps to get to a healthy weight. The liver is one of the few organs in your body that can replace damaged tissue with new cells rather than with scar tissue. But that reversal only works if you don’t drink alcohol and follow a healthy lifestyle. […] Vitamin E. Studies have shown that vitamin E could improve liver health by reducing inflammation, but the results varied depending on the dosage, patient’s age, and how overweight they were. Also, some studies showed that high doses of vitamin E could be dangerous for people with other medical conditions as well as FLD.

• #81 Non-Alcoholic Fatty Liver Disease (NAFLD): Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/digestive/liver-diseases/fatty-liver-disease-non-alcoholic/treatment

  Severe liver cirrhosis can be life-threatening, which may increase the need for a liver transplant. […] While no medication is specifically used to treat NAFLD, promising drugs are under study in clinical trials. If interested, you can participate in one of these trials, supervised by your doctor. […] Following a healthy lifestyle that involves eating a healthy diet and being physically active helps. Weight loss through these changes, use of weight loss medications, and/or bariatric procedures may all lead to improvement in NAFLD. […] Most individuals with non-alcoholic fatty liver disease experience significant symptoms such as leg swelling, nausea, and abdominal pain once the NAFLD reaches advanced stages. Recognizing signs and symptoms and getting checkups to test your liver’s condition are essential to liver health. […] At NewYork-Presbyterian, you can receive all the care you need. Call to schedule an appointment today for fatty liver disease treatment.

• #82 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis. […] All patients with NAFLD require advice about lifestyle modification aimed at weight loss and increased physical activity, as well as treatment of any associated metabolic risk factors (diabetes, hypertension and dyslipidaemia). […] Patients with steatohepatitis and fibrosis are at highest risk of developing progressive liver disease so require more aggressive lifestyle modification and if this fails can be considered for liver-directed pharmacotherapy with pioglitazone or vitamin E.

• #83 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Diabetes control – Strict management of diabetes with diet, medications or insulin lowers blood sugar, which may prevent further liver damage. It may also reduce the amount of accumulated fat in your liver. […] Cholesterol control – Controlling elevated levels of cholesterol and triglycerides with diet, exercise and cholesterol-lowering medications may help stabilize or reverse nonalcoholic fatty liver disease. […] Avoidance of toxic substances – If you have nonalcoholic fatty liver disease especially nonalcoholic steatohepatitis (NASH) don’t drink alcohol. Also avoid medications and other substances that can cause liver damage. Talk to your doctor about which drugs to avoid. […] Several possible treatments are under investigation, but so far none has proved effective. These approaches include: Vitamins E and C – Since both vitamins are antioxidants, it’s thought that they may reduce liver damage caused by oxidants, unstable oxygen molecules that damage cell membranes. […] Bariatric surgery – While abdominal weight-loss surgery coupled with rapid weight loss has been implicated as contributing to the development of NASH, some research suggests that bariatric surgery combined with modest weight loss may reduce the inflammation and scarring associated with NASH.

• #84 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Diabetes control – Strict management of diabetes with diet, medications or insulin lowers blood sugar, which may prevent further liver damage. It may also reduce the amount of accumulated fat in your liver. […] Cholesterol control – Controlling elevated levels of cholesterol and triglycerides with diet, exercise and cholesterol-lowering medications may help stabilize or reverse nonalcoholic fatty liver disease. […] Avoidance of toxic substances – If you have nonalcoholic fatty liver disease especially nonalcoholic steatohepatitis (NASH) don’t drink alcohol. Also avoid medications and other substances that can cause liver damage. Talk to your doctor about which drugs to avoid. […] Several possible treatments are under investigation, but so far none has proved effective. These approaches include: Vitamins E and C – Since both vitamins are antioxidants, it’s thought that they may reduce liver damage caused by oxidants, unstable oxygen molecules that damage cell membranes. […] Bariatric surgery – While abdominal weight-loss surgery coupled with rapid weight loss has been implicated as contributing to the development of NASH, some research suggests that bariatric surgery combined with modest weight loss may reduce the inflammation and scarring associated with NASH.

• #85 Nonalcoholic fatty liver – La Crosse – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/locations/la-crosse/services-and-treatments/gastroenterology-and-hepatology/digestive-disorders/nonalcoholic-fatty-liver-disease

  Control your diabetes. Follow your doctor’s instructions to stay in control of your diabetes. Take your medications as directed and closely monitor your blood sugar. […] Lower your cholesterol. A healthy plant-based diet, exercise and medications can help keep your cholesterol and your triglycerides at healthy levels. […] Protect your liver. Avoid things that will put extra stress on your liver. For instance, don’t drink alcohol. Follow the instructions on all medications and over-the-counter drugs. Check with your doctor before using any herbal remedies, as not all herbal products are safe.

• #86 Nonalcoholic fatty liver – La Crosse – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/locations/la-crosse/services-and-treatments/gastroenterology-and-hepatology/digestive-disorders/nonalcoholic-fatty-liver-disease

  Control your diabetes. Follow your doctor’s instructions to stay in control of your diabetes. Take your medications as directed and closely monitor your blood sugar. […] Lower your cholesterol. A healthy plant-based diet, exercise and medications can help keep your cholesterol and your triglycerides at healthy levels. […] Protect your liver. Avoid things that will put extra stress on your liver. For instance, don’t drink alcohol. Follow the instructions on all medications and over-the-counter drugs. Check with your doctor before using any herbal remedies, as not all herbal products are safe.

• #87 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Diabetes control – Strict management of diabetes with diet, medications or insulin lowers blood sugar, which may prevent further liver damage. It may also reduce the amount of accumulated fat in your liver. […] Cholesterol control – Controlling elevated levels of cholesterol and triglycerides with diet, exercise and cholesterol-lowering medications may help stabilize or reverse nonalcoholic fatty liver disease. […] Avoidance of toxic substances – If you have nonalcoholic fatty liver disease especially nonalcoholic steatohepatitis (NASH) don’t drink alcohol. Also avoid medications and other substances that can cause liver damage. Talk to your doctor about which drugs to avoid. […] Several possible treatments are under investigation, but so far none has proved effective. These approaches include: Vitamins E and C – Since both vitamins are antioxidants, it’s thought that they may reduce liver damage caused by oxidants, unstable oxygen molecules that damage cell membranes. […] Bariatric surgery – While abdominal weight-loss surgery coupled with rapid weight loss has been implicated as contributing to the development of NASH, some research suggests that bariatric surgery combined with modest weight loss may reduce the inflammation and scarring associated with NASH.

• #88 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  Most people with NAFLD will not develop any serious problems, but if you’re diagnosed with the condition it’s a good idea to take steps to stop it getting any worse. […] There’s currently no specific medication for NAFLD, but making healthy lifestyle choices can help. […] Treatment also may be recommended for associated conditions (high blood pressure, diabetes and cholesterol) or complications. […] You may be advised to have regular appointments with your doctor to check your liver function and look for signs of any new problems. […] There’s not currently any medicine that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medicine to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and treat obesity.

• #89 Nonalcoholic fatty liver – La Crosse – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/locations/la-crosse/services-and-treatments/gastroenterology-and-hepatology/digestive-disorders/nonalcoholic-fatty-liver-disease

  Control your diabetes. Follow your doctor’s instructions to stay in control of your diabetes. Take your medications as directed and closely monitor your blood sugar. […] Lower your cholesterol. A healthy plant-based diet, exercise and medications can help keep your cholesterol and your triglycerides at healthy levels. […] Protect your liver. Avoid things that will put extra stress on your liver. For instance, don’t drink alcohol. Follow the instructions on all medications and over-the-counter drugs. Check with your doctor before using any herbal remedies, as not all herbal products are safe.

• #90 Non-alcoholic fatty liver disease (NAFLD) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/non-alcoholic-fatty-liver-disease-nafld/

  Exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week. All types of exercise can help improve NAFLD, even if you dont lose weight. […] Stop smoking if you smoke, stopping can help reduce your risk of problems such as heart attacks and strokes. […] NAFLD isnt caused by alcohol, but drinking may make the condition worse. Its therefore advisable to cut down or stop drinking alcohol. […] There isnt currently any medication that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medication to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and/or treat obesity. […] If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant.

• #91 Non-Alcoholic Fatty Liver Disease | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/digestive-and-liver-health/fatty-liver-disease-non-alcoholic

  Improving other metabolic diseases such as diabetes, high blood pressure and high cholesterol/lipids can also help NAFLD. […] Moderate or heavy alcohol use can cause additional damage and fat accumulation in the liver in people with NAFLD. Therefore, patients with NAFLD should avoid alcohol entirely if possible. If you do not think you can completely stop drinking alcohol, it is important to minimize alcohol intake (less than 2 drinks per day for men and 1 drink per day for women). […] At the University of Michigan Fatty Liver Disease Clinic, we provide the latest diagnostic and treatment options to patients with NAFLD/NASH, as well as access to cutting edge research trials that include new therapies under study.

• #92 Nonalcoholic fatty liver – La Crosse – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/locations/la-crosse/services-and-treatments/gastroenterology-and-hepatology/digestive-disorders/nonalcoholic-fatty-liver-disease

  Control your diabetes. Follow your doctor’s instructions to stay in control of your diabetes. Take your medications as directed and closely monitor your blood sugar. […] Lower your cholesterol. A healthy plant-based diet, exercise and medications can help keep your cholesterol and your triglycerides at healthy levels. […] Protect your liver. Avoid things that will put extra stress on your liver. For instance, don’t drink alcohol. Follow the instructions on all medications and over-the-counter drugs. Check with your doctor before using any herbal remedies, as not all herbal products are safe.

• #93 Nonalcoholic fatty liver – La Crosse – Mayo Clinic Health System

  https://www.mayoclinichealthsystem.org/locations/la-crosse/services-and-treatments/gastroenterology-and-hepatology/digestive-disorders/nonalcoholic-fatty-liver-disease

  Control your diabetes. Follow your doctor’s instructions to stay in control of your diabetes. Take your medications as directed and closely monitor your blood sugar. […] Lower your cholesterol. A healthy plant-based diet, exercise and medications can help keep your cholesterol and your triglycerides at healthy levels. […] Protect your liver. Avoid things that will put extra stress on your liver. For instance, don’t drink alcohol. Follow the instructions on all medications and over-the-counter drugs. Check with your doctor before using any herbal remedies, as not all herbal products are safe.

• #94 Steatotic (Fatty) Liver Disease: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/15831-fatty-liver-disease

  Theres no specific treatment or medications. Instead, providers focus on helping you manage risk factors that contribute to the condition. This includes making lifestyle changes that can improve your health. […] Your provider may recommend that you: […] Avoid alcohol: Steer clear of alcohol even if your SLD isnt related to alcohol use. […] Lose weight: Exercising, changing what you eat and drink (under the supervision of a nutritionist) and taking medications, such as GLP1RA, can help with weight loss. You may qualify for bariatric surgery, which can also help you lose weight. […] Take medications to manage metabolic conditions: Take prescribed medicines to manage diabetes, cholesterol and triglycerides (fat in the blood). You may also need to take vitamin E and thiazolidinediones (drugs used to treat diabetes, such as Actos and Avandia) in specific instances. […] Get vaccinated for hepatitis A and hepatitis B: These viral infections are especially dangerous if you already have liver disease. […] Your provider may change your prescriptions if your medicine is causing fat to accumulate in your liver.

• #95 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  A multidisciplinary approach to treatment that involves nutritionists, endocrinologists, cardiologists, and other specialists as needed in addition to your hepatologist is essential to successfully manage the underlying metabolic conditions associated with fatty liver disease. […] In March 2024, the US Food and Drug Administration approved the use of resmetirom (Rezdiffra) for people with NASH and stage 2 or 3 fibrosis (but not cirrhosis) along with eating a healthy diet and participating in regular exercise. This is the first drug approved for NASH in the United States and the approval was based on resolution of NASH and improvement in fibrosis in about a quarter of the patients treated in a large international trial (MAESTRO NASH, NCT03900429). […] Some evidence suggests vitamin E supplements may be helpful for people with liver damage due to NAFLD and NASH. Researchers in one study found that a daily dose of the natural form of vitamin E the kind that comes from food sources and isnt made in a laboratory improved NASH in study participants overall by reducing fat and inflammation although not scarring.

• #96 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  A multidisciplinary approach to treatment that involves nutritionists, endocrinologists, cardiologists, and other specialists as needed in addition to your hepatologist is essential to successfully manage the underlying metabolic conditions associated with fatty liver disease. […] In March 2024, the US Food and Drug Administration approved the use of resmetirom (Rezdiffra) for people with NASH and stage 2 or 3 fibrosis (but not cirrhosis) along with eating a healthy diet and participating in regular exercise. This is the first drug approved for NASH in the United States and the approval was based on resolution of NASH and improvement in fibrosis in about a quarter of the patients treated in a large international trial (MAESTRO NASH, NCT03900429). […] Some evidence suggests vitamin E supplements may be helpful for people with liver damage due to NAFLD and NASH. Researchers in one study found that a daily dose of the natural form of vitamin E the kind that comes from food sources and isnt made in a laboratory improved NASH in study participants overall by reducing fat and inflammation although not scarring.

• #97 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #98 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #99 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #100 Therapies for non-alcoholic fatty liver disease: A 2022 update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9521452/

  Currently, a multitude of NAFLD therapies are in phase 3 trials including dapagliflozin, semaglutide, resmetirom, obeticholic acid, and aramchol, with more in development. The current trajectory likely involves tailoring drug therapies for different phases of NAFLD, such as utilizing aramchol or NGM282 for reduction of hepatic fat in patients with simple steatosis vs dapagliflozin in patients with fibrosis. Furthermore, combination therapies are also being studied in phase 2 trials. Due to the complex pathophysiology of NAFLD, these regimens will likely also be effective, but their safety, tolerability, and optimal drug combination must be assessed.

• #101 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/24/3/2844

  SGLT-2 suppressors, as the latest group of antidiabetic medications, inhibit kidney glucose reabsorption, which results in prominent glycosuria. […] Obeticholic acid, elafibranor, selonsertib and cenicriviroc are presently in phase III randomized controlled studies for assessing their possible therapeutic values in NAFLD. […] Bariatric surgery ameliorates liver fat and may even alleviate all histological lesions in NASH, e.g., fibrosis.

• #102 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  There are things people can do to lower their chances of developing NAFLD (now called MASLD). They include: Maintain a healthy weight. Eat meals that contain lean proteins, whole grains, fruits, vegetables, healthy oils, and low-fat dairy products. Try to include some kind of physical movement during most days of the week. If you are not currently physically active, speak with your doctor about the types of activities you can do that are safe for your current physical abilities. Limit or avoid alcohol intake. Only take medicines that you need and follow dosing recommendations. […] Once NAFLD is determined, management of the condition focuses on lifestyle interventions (health dietary modifications and appropriate physical activities permitted during pregnancy) as there are no approved medications for NAFLD in pregnancy. Prior to pregnancy, preconception counseling, weight management, and optimal blood sugar control are important measures for preventing the development or progression of NAFLD. Importantly, breastfeeding may reduce NAFLD risk for both the mother and their child. Ultimately, close monitoring during pregnancy is crucial to reduce risks and improve outcomes for both the mother and her child. […] Speak with your doctor about the ongoing progress and results of these trials to get the most up-to-date information on new treatments. Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications.

• #103 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  There are things people can do to lower their chances of developing NAFLD (now called MASLD). They include: Maintain a healthy weight. Eat meals that contain lean proteins, whole grains, fruits, vegetables, healthy oils, and low-fat dairy products. Try to include some kind of physical movement during most days of the week. If you are not currently physically active, speak with your doctor about the types of activities you can do that are safe for your current physical abilities. Limit or avoid alcohol intake. Only take medicines that you need and follow dosing recommendations. […] Once NAFLD is determined, management of the condition focuses on lifestyle interventions (health dietary modifications and appropriate physical activities permitted during pregnancy) as there are no approved medications for NAFLD in pregnancy. Prior to pregnancy, preconception counseling, weight management, and optimal blood sugar control are important measures for preventing the development or progression of NAFLD. Importantly, breastfeeding may reduce NAFLD risk for both the mother and their child. Ultimately, close monitoring during pregnancy is crucial to reduce risks and improve outcomes for both the mother and her child. […] Speak with your doctor about the ongoing progress and results of these trials to get the most up-to-date information on new treatments. Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications.

• #104 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  Early diagnosis of NAFLD, along with following medical advice, can reduce a persons chance NAFLD progressing to NASH and cirrhosis. […] There are no medications approved yet for nonalcoholic fatty liver disease (now called MASLD). Eating a healthy diet and adding physical movement to your day may help prevent liver damage from starting or reverse it in the initial stages. Here are suggestions for people who have NAFLD: See a liver specialist (gastroenterologist or hepatologist) to monitor and advise you about your liver health. If you are overweight or obese, speak to your doctor or a dietitian to learn more about planning healthy meals that can help you lose weight. If you have high cholesterol or high triglycerides, speak with your doctor about how to lower your numbers to a healthier range. If you have diabetes, speak with your doctor about managing your condition. Avoid alcohol (beer, wine, hard liquor) to lower the risk of additional liver damage.

• #105 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  Early diagnosis of NAFLD, along with following medical advice, can reduce a persons chance NAFLD progressing to NASH and cirrhosis. […] There are no medications approved yet for nonalcoholic fatty liver disease (now called MASLD). Eating a healthy diet and adding physical movement to your day may help prevent liver damage from starting or reverse it in the initial stages. Here are suggestions for people who have NAFLD: See a liver specialist (gastroenterologist or hepatologist) to monitor and advise you about your liver health. If you are overweight or obese, speak to your doctor or a dietitian to learn more about planning healthy meals that can help you lose weight. If you have high cholesterol or high triglycerides, speak with your doctor about how to lower your numbers to a healthier range. If you have diabetes, speak with your doctor about managing your condition. Avoid alcohol (beer, wine, hard liquor) to lower the risk of additional liver damage.

• #106 Nonalcoholic Fatty Liver Disease: Symptoms, Causes, and More

  https://www.healthline.com/health/nonalcoholic-fatty-liver-disease

  There is no specific medication or procedure to treat NAFLD. Instead, your doctor will most likely recommend several important lifestyle changes. These include: […] If you’ve been diagnosed with nonalcoholic fatty liver disease, sticking to recommended lifestyle changes may be enough to preserve good liver health for a long time. You may even be able to reverse liver damage in the earliest stages of the disease. […] The good news is that the same lifestyle choices that can manage NAFLD can also help manage, or reverse, other health issues such as type 2 diabetes, high cholesterol, and metabolic syndrome.

• #107 Nonalcoholic Fatty Liver Disease: Symptoms, Causes, and More

  https://www.healthline.com/health/nonalcoholic-fatty-liver-disease

  There is no specific medication or procedure to treat NAFLD. Instead, your doctor will most likely recommend several important lifestyle changes. These include: […] If you’ve been diagnosed with nonalcoholic fatty liver disease, sticking to recommended lifestyle changes may be enough to preserve good liver health for a long time. You may even be able to reverse liver damage in the earliest stages of the disease. […] The good news is that the same lifestyle choices that can manage NAFLD can also help manage, or reverse, other health issues such as type 2 diabetes, high cholesterol, and metabolic syndrome.

Zobacz więcej